N. Latov, Diagnosis and treatment of chronic acquired demyelinating polyneuropathies, Nat Rev Neurol, vol.10, pp.435-481, 2014.

E. Ellie, A. Vital, and A. Steck, Neuropathy associated with "benign" anti-myelin-associated glycoprotein IgM gammopathy: clinical, immunological, neurophysiological pathological findings and response to treatment in 33 cases, J Neurol, vol.243, pp.34-43, 1996.

J. Niermeijer, K. Fischer, and M. Eurelings, Prognosis of polyneuropathy due to IgM monoclonal gammopathy: a prospective cohort study, Neurology, vol.74, pp.406-418, 2010.

M. Hospital, K. Viala, and S. Dragomir, Immunotherapy-based regimen in anti-MAG neuropathy: results in 45 patients, Haematologica, vol.98, pp.155-162, 2013.

E. Nobile-orazio, N. Meucci, and L. Baldini, Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies, Brain, vol.123, pp.710-717, 2000.

M. Pruppers, I. Merkies, and N. C. Notermans, Recent advances in outcome measures in IgM-antiMAG+ neuropathies, Curr Opin Neurol, vol.28, pp.486-93, 2015.

, European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies, Joint Task Force of the EFNS and the PNS, vol.15, pp.185-95, 2010.

M. Lunn, T. O. Crawford, and R. Hughes, Anti-myelin-associated glycoprotein antibodies alter neurofilament spacing, Brain, vol.125, pp.904-915, 2002.

A. P. Hays, N. Latov, and M. Takatsu, Experimental demyelination of nerve induced by serum of patients with neuropathy and an anti-MAG IgM M-protein, Neurology, vol.37, pp.242-56, 1987.

E. Nobile-orazio, P. Marmiroli, and L. Baldini, Peripheral neuropathy in macroglobulinemia: incidence and antigen-specificity of M proteins, Neurology, vol.37, pp.1506-1520, 1987.

J. M. Jacobs, Morphological changes at paranodes in IgM paraproteinaemic neuropathy, Microsc Res Tech, vol.34, pp.544-53, 1996.

V. N. Ngo, R. M. Young, and R. Schmitz, Oncogenically active MYD88 mutations in human lymphoma, Nature, vol.470, pp.115-124, 2011.

S. P. Treon, L. Xu, and G. Yang, MYD88 L265P somatic mutation in Waldenström's macroglobulinemia, N Engl J Med, vol.367, pp.826-859, 2012.

O. Landgren and L. Staudt, MYD88 L265P somatic mutation in IgM MGUS, N Engl J Med, vol.367, pp.2256-2263, 2012.

M. Varettoni, S. Zibellini, and L. Arcaini, MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance, Blood, vol.122, pp.2284-2289, 2013.

L. Xu, Z. R. Hunter, and G. Yang, MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction, Blood, vol.121, pp.2051-2059, 2013.

J. M. Busillo and J. L. Benovic, Regulation of CXCR4 signaling, Biochim Biophys Acta, vol.1768, pp.952-63, 2007.

J. M. Busillo, S. Armando, and R. Sengupta, Site-specific phosphorylation of CXCR4 is dynamically regulated by multiple kinases and results in differential modulation of CXCR4 signaling, J Biol Chem, vol.285, pp.7805-7822, 2010.

Z. R. Hunter, L. Xu, and G. Yang, The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis, Blood, vol.123, pp.1637-1683, 2014.

S. P. Treon, Y. Cao, and L. Xu, Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia, Blood, vol.123, pp.2791-2797, 2014.

L. Dotta, L. Tassone, and R. Badolato, Clinical and genetic features of Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) syndrome, Curr Mol Med, vol.11, pp.317-342, 2011.

F. Nguyen-khac, J. Lambert, and E. Chapiro, Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia, Haematologica, vol.98, pp.649-54, 2013.

L. Wang, M. S. Lawrence, and Y. Wan, SF3B1 and other novel cancer genes in chronic lymphocytic leukemia, N Engl J Med, vol.365, pp.2497-506, 2011.

X. S. Puente, M. Pinyol, and V. Quesada, Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia, Nature, vol.475, pp.101-106, 2011.

R. Guièze, P. Robbe, and R. Clifford, Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL, Blood, vol.126, pp.2110-2117, 2015.

E. Campo, S. H. Swerdlow, and N. L. Harris, WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications, Blood, vol.117, pp.5019-5051, 2008.

R. G. Owen, S. P. Treon, and A. Al-katib, Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia, Semin Oncol, vol.30, pp.110-115, 2003.

S. H. Swerdlow, E. Campo, and S. A. Pileri, The 2016 revision of the World Health Organization classification of lymphoid neoplasms, Blood, vol.127, pp.2375-90, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01800015

W. J. Kent, C. W. Sugnet, and T. S. Furey, The human genome browser at UCSC, Genome Res, vol.12, pp.996-1006, 2002.

S. A. Forbes, D. Beare, and P. Gunasekaran, COSMIC: exploring the world's knowledge of somatic mutations in human cancer, Nucleic Acids Res, vol.43, pp.805-816, 2015.

M. Lek, K. J. Karczewski, and E. V. Minikel, Analysis of protein-coding genetic variation in 60,706 humans, Nature, vol.536, pp.285-91, 2016.

I. A. Adzhubei, S. Schmidt, and L. Peshkin, A method and server for predicting damaging missense mutations, Nat Methods, vol.7, pp.248-257, 2010.

P. C. Ng and S. Henikoff, SIFT: Predicting amino acid changes that affect protein function, Nucleic Acids Res, vol.31, pp.3812-3816, 2003.

J. Léger, K. Viala, and G. Nicolas, Placebo-controlled trial of rituximab in IgM anti-myelinassociated glycoprotein neuropathy, Neurology, vol.80, pp.2217-2242, 2013.

L. Magy, R. Kaboré, and S. Mathis, Heterogeneity of Polyneuropathy Associated with Anti-MAG Antibodies, J Immunol Res, p.450391, 2015.

L. Xu, Z. R. Hunter, and G. Yang, Detection of MYD88 L265P in peripheral blood of patients with Waldenström's Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance, Leukemia, vol.28, pp.1698-704, 2014.

C. Jiménez, E. Sebastián, and M. C. Chillón, MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia, Leukemia, vol.27, pp.1722-1730, 2013.

S. Poulain, C. Roumier, and A. Decambron, MYD88 L265P mutation in Waldenstrom macroglobulinemia, Blood, vol.121, pp.4504-4515, 2013.

J. Schmidt, B. Federmann, and N. Schindler, MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity, Br J Haematol, vol.169, pp.795-803, 2015.

K. S. Hathcock, H. M. Padilla-nash, and J. Camps, ATM deficiency promotes development of murine B-cell lymphomas that resemble diffuse large B-cell lymphoma in humans, Blood, vol.126, pp.2291-301, 2015.

K. Grønbaek, J. Worm, and E. Ralfkiaer, ATM mutations are associated with inactivation of the ARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma, Blood, vol.100, pp.1430-1437, 2002.

C. Schaffner, S. Stilgenbauer, and G. A. Rappold, Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia, Blood, vol.94, pp.748-53, 1999.

B. Austen, J. E. Powell, and A. Alvi, Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL, Blood, vol.106, pp.3175-82, 2005.

A. Skowronska, B. Austen, and J. E. Powell, ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele, Haematologica, vol.97, pp.142-148, 2012.

F. Nadeu, J. Delgado, and C. Royo, Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia, Blood, vol.127, pp.2122-2152, 2016.

V. Rotter, R. Aloni-grinstein, and D. Schwartz, Does wild-type p53 play a role in normal cell differentiation?, Semin Cancer Biol, vol.5, pp.229-265, 1994.

P. Shaw, J. Freeman, and R. Bovey, Regulation of specific DNA binding by p53: evidence for a role for O-glycosylation and charged residues at the carboxy-terminus, Oncogene, vol.12, pp.921-951, 1996.

D. Wynford-thomas, Cellular senescence and cancer, J Pathol, vol.187, pp.100-111, 1999.

J. Kruse and W. Gu, Modes of p53 regulation, Cell, vol.137, pp.609-631, 2009.

C. Preudhomme and P. Fenaux, The clinical significance of mutations of the P53 tumour suppressor gene in haematological malignancies, Br J Haematol, vol.98, pp.502-513, 1997.

N. Rivlin, R. Brosh, and M. Oren, Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis, Genes Cancer, vol.2, pp.466-74, 2011.

W. Vainchenker, F. Delhommeau, and S. N. Constantinescu, New mutations and pathogenesis of myeloproliferative neoplasms, Blood, vol.118, pp.1723-1758, 2011.

C. N. Hahn and H. S. Scott, Spliceosome mutations in hematopoietic malignancies, Nat Genet, vol.44, pp.9-10, 2012.

V. Quesada, A. J. Ramsay, and C. Lopez-otin, Chronic lymphocytic leukemia with SF3B1 mutation, N Engl J Med, vol.366, p.2530, 2012.

V. Quesada, L. Conde, and N. Villamor, Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia, Nat Genet, vol.44, pp.47-52, 2012.

D. G. Oscier, M. Rose-zerilli, and N. Winkelmann, The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial, Blood, vol.121, pp.468-75, 2013.

D. Bellavia, A. F. Campese, and E. Alesse, Constitutive activation of NF-kappaB and T-cell leukemia/lymphoma in Notch3 transgenic mice, EMBO J, vol.19, pp.3337-3385, 2000.

S. Lee, K. Kumano, and S. Masuda, Mutations of the Notch1 gene in T-cell acute lymphoblastic leukemia: analysis in adults and children, Leukemia, vol.19, pp.1841-1844, 2005.

E. Rosati, R. Sabatini, and G. Rampino, Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells, Blood, vol.113, pp.856-65, 2009.

A. A. Filip, New boys in town: prognostic role of SF3B1, NOTCH1 and other cryptic alterations in chronic lymphocytic leukemia and how it works, Leuk Lymphoma, vol.54, pp.1876-81, 2013.

V. Balatti, S. Lerner, and L. Rizzotto, Trisomy 12 CLLs progress through NOTCH1 mutations, Leukemia, vol.27, pp.740-743, 2013.
DOI : 10.1038/leu.2012.239

URL : http://europepmc.org/articles/pmc3733494?pdf=render

R. G. Wickremasinghe, A. G. Prentice, and A. J. Steele, p53 and Notch signaling in chronic lymphocytic leukemia: clues to identifying novel therapeutic strategies, Leukemia, vol.25, pp.1400-1407, 2011.
DOI : 10.1038/leu.2011.103

URL : http://www.nature.com/leu/journal/v25/n9/pdf/leu2011103a.pdf

D. A. Arber and T. I. George, Bone marrow biopsy involvement by non-Hodgkin's lymphoma: frequency of lymphoma types, patterns, blood involvement, and discordance with other sites in 450 specimens, Am J Surg Pathol, vol.29, pp.1549-57, 2005.

V. Sovani, C. Harvey, and A. P. Haynes, Bone marrow trephine biopsy involvement by lymphoma: review of histopathological features in 511 specimens and correlation with diagnostic biopsy, aspirate and peripheral blood findings, J Clin Pathol, vol.67, pp.389-95, 2014.

L. Xu, Z. R. Hunter, and G. Yang, Detection of MYD88 L265P in peripheral blood of patients with Waldenström's Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance, Leukemia, vol.28, pp.1698-704, 2014.

A. M. Roccaro, A. Sacco, and C. Jimenez, C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma, Blood, vol.123, pp.4120-4151, 2014.

L. Xu, Z. R. Hunter, and N. Tsakmaklis, Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia, Br J Haematol, vol.172, pp.735-779, 2016.

E. Nobile-orazio, F. Gallia, and F. Terenghi, How useful are anti-neural IgM antibodies in the diagnosis of chronic immune-mediated neuropathies?, J Neurol Sci, vol.266, pp.156-63, 2008.

M. Mahdi-rogers and . Hughes-r-a.-c, Epidemiology of chronic inflammatory neuropathies in southeast England, Eur J Neurol, vol.21, pp.28-33, 2014.

M. Lunn and E. Nobile-orazio, Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies, Cochrane Database Syst Rev, p.2827, 2012.
DOI : 10.1002/14651858.cd002827

URL : https://air.unimi.it/bitstream/2434/481190/2/LunnNobileOrazio_TheCochraneLibrary_ImmunotherapyIgM_2016.pdf

T. M. Watters, E. F. Kenny, O. Neill, and L. , Structure, function and regulation of the Toll/IL-1 receptor adaptor proteins, Immunol Cell Biol, vol.85, pp.411-420, 2007.

M. Loiarro, G. Gallo, and N. Fantò, Identification of critical residues of the MyD88 death domain involved in the recruitment of downstream kinases, J Biol Chem, vol.284, pp.28093-103, 2009.

S. Lin, Y. Lo, and H. Wu, Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling, Nature, vol.465, pp.885-90, 2010.

G. Yang, Y. Zhou, and X. Liu, A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia, Blood, vol.122, pp.1222-1254, 2013.

L. A. Honigberg, A. M. Smith, and M. Sirisawad, The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy, Proc Natl Acad Sci, vol.107, pp.13075-80, 2010.

S. P. Treon, C. K. Tripsas, and K. Meid, Ibrutinib in previously treated Waldenström's macroglobulinemia, N Engl J Med, vol.372, pp.1430-1470, 2015.
DOI : 10.1056/nejmoa1501548